Preserving the intellectual output & resources of the University of Missouri.
Annual zoledronic acid infusion lowers risk of fracture, death
MOspace/Manakin Repository
Breadcrumbs Navigation
Annual zoledronic acid infusion lowers risk of fracture, death
Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/5403
| Title: | Annual zoledronic acid infusion lowers risk of fracture, death |
| Author: | Schumann, Sarah-Anne; Hickner, John |
| Keywords: |
hip fracture
bisphosphonate zoledronic acid |
| Date: | 2007-12 |
| Publisher: | Family Physicians Inquiries Network |
| Citation: | Journal of Family Practice, 56(12) 2007: 1013-1016. |
| Abstract: | Patients with a prior hip fracture have 2.5 times the risk of a new fracture compared to age-matched persons without a previous hip fracture. For patients with a recent hip fracture, intravenous zoledronic acid annually is an option for reducing the risk of new fractures and death. Strength of recommendation (SOR) B: based on one well- designed randomized controlled trial. |
| URI: | http://hdl.handle.net/10355/5403 |
Items in MOspace are protected by copyright, with all rights reserved, unless otherwise indicated.
This item appears in the following Collection(s)
-
Priority Updates to Research Literature (PURLs) [107]
Priority Updates to Research Literature generate new evidence-based recommendations for practice for family physicians and other primary care clinicians.